This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Yu, H. A. et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor–mutated non–small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J. Clin. Oncol. https://doi.org/10.1200/JCO.23.01476 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. Patritumab deruxtecan shows activity in EGFR-mutant NSCLC. Nat Rev Clin Oncol 20, 817 (2023). https://doi.org/10.1038/s41571-023-00822-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00822-6